- Home
- WRBY vs VRDN Comparison
WRBY vs VRDN Comparison
Compare WRBY & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRBY | VRDN |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | WRBY | VRDN |
|---|---|---|
| Price | $26.53 | $32.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $25.43 | ★ $41.17 |
| AVG Volume (30 Days) | ★ 3.8M | 1.4M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $850,580,000.00 | $70,789,000.00 |
| Revenue This Year | $15.66 | $26,257.62 |
| Revenue Next Year | $12.88 | $4.54 |
| P/E Ratio | $11,018.11 | ★ N/A |
| Revenue Growth | 14.55 | ★ 23340.07 |
| 52 Week Low | $13.63 | $9.90 |
| 52 Week High | $31.00 | $34.29 |
Technical Indicators
Market Signals| Indicator | WRBY | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 56.35 |
| Support Level | $26.09 | $31.26 |
| Resistance Level | $30.00 | $33.35 |
| Average True Range (ATR) | 1.57 | 1.30 |
| MACD | -0.23 | 0.02 |
| Stochastic Oscillator | 16.71 | 69.85 |
Price Performance
Historical ComparisonAbout WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).